Michael Zile to Adolescent
This is a "connection" page, showing publications Michael Zile has written about Adolescent.
Connection Strength
0.087
-
A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design. J Card Fail. 2004 Jun; 10(3):193-9.
Score: 0.024
-
Non-invasive MR imaging of human brain lymphatic networks with connections to cervical lymph nodes. Nat Commun. 2022 01 11; 13(1):203.
Score: 0.020
-
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015 Nov 10; 66(19):2059-2071.
Score: 0.013
-
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015 Oct 07; 36(38):2576-84.
Score: 0.013
-
A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study. J Thromb Thrombolysis. 2005 Dec; 20(3):147-53.
Score: 0.007
-
A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003 Oct; 9(5):354-63.
Score: 0.006
-
beta-Adrenergic and endothelin receptor interaction in dilated human cardiomyopathic myocardium. J Card Fail. 2001 Jun; 7(2):129-37.
Score: 0.005
-
Immunologic tests of value in diagnosis. 1. Acute phase reactants and autoantibodies. Postgrad Med. 1981 Aug; 70(2):163-78.
Score: 0.001